Covered recipient · General Payments record
SRIDHAR GUDURI
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,126.47
75 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,020.47 | 73 |
| Education | $106.00 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $802.23 | 20 |
| GENZYME CORPORATION | $414.51 | 20 |
| Amgen Inc. | $221.18 | 9 |
| Novartis Pharmaceuticals Corporation | $177.74 | 9 |
| Insmed, Inc. | $146.21 | 1 |
| SANOFI-AVENTIS U.S. LLC | $72.00 | 1 |
| Regeneron Healthcare Solutions, Inc. | $65.62 | 3 |
| Grifols USA, LLC | $36.72 | 2 |
| Optinose US, Inc. | $34.96 | 2 |
| Genentech USA, Inc. | $28.44 | 1 |
| ARS Pharmaceuticals Operations, Inc. | $24.27 | 1 |
| CSL Behring | $20.76 | 1 |
| Pharming Healthcare, Inc. | $18.41 | 1 |
| Paratek Pharmaceuticals, Inc. | $18.11 | 1 |
| Blueprint Medicines Corporation | $17.25 | 1 |
| Hikma Pharmaceuticals USA | $15.71 | 1 |
| PFIZER INC. | $12.35 | 1 |
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SRIDHAR GUDURI
NPI 1669436192 · CMS profile ID 210894
Allopathic & Osteopathic Physicians / Allergy & Immunology
DUBLIN, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SRIDHAR GUDURI, NPI 1669436192, CMS profile ID 210894, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669436192?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
75 matching records · $2,126.47 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–75 of 75.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals USA | $15.71 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248218330 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.17 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206538838 | CMS |
| AstraZeneca Pharmaceuticals LP | $111.56 | 04/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206713657 | CMS |
| GENZYME CORPORATION | $9.62 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373558 | CMS |
| PFIZER INC. | $12.35 | 04/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229067366 | CMS |
| Pharming Healthcare, Inc. | $18.41 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200797983 | CMS |
| GENZYME CORPORATION | $11.73 | 03/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373538 | CMS |
| GENZYME CORPORATION | $11.86 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373534 | CMS |
| Optinose US, Inc. | $17.79 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1163254242 | CMS |
| Genentech USA, Inc. | $28.44 | 03/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211591818 | CMS |
| Amgen Inc. | $17.01 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228588411 | CMS |
| GENZYME CORPORATION | $92.50 | 03/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373526 | CMS |
| Novartis Pharmaceuticals Corporation | $53.02 | 02/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200210790 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.12 | 02/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206191403 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.67 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206601286 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.94 | 02/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206876615 | CMS |
| Amgen Inc. | $7.89 | 02/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227185909 | CMS |
| AstraZeneca Pharmaceuticals LP | $173.04 | 02/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207120880 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.07 | 01/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206292390 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.36 | 01/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207138500 | CMS |
| GENZYME CORPORATION | $15.53 | 01/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373504 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.76 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206212913 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.73 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206376086 | CMS |
| Amgen Inc. | $5.05 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1227185905 | CMS |
| GENZYME CORPORATION | $21.57 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233373500 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,950,529.31 | 645 |
| PY2024 | Recipient | $43,825.25 | 17 |
| PY2024 | Principal investigator | $2,746,480.16 | 466 |
| PY2023 | Recipient | $535.01 | 1 |
| PY2023 | Principal investigator | $2,561,960.55 | 951 |
| PY2022 | Principal investigator | $1,562,855.45 | 131 |
| PY2021 | Principal investigator | $254,191.94 | 34 |
| PY2020 | Principal investigator | $106,758.78 | 18 |
| PY2019 | Recipient | $54.90 | 1 |
| PY2019 | Principal investigator | $89,894.48 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
645 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202535103 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202535105 |
| Principal investigator 1 | PFIZER INC. | $4,739.00 | 12/31/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228815950 |
| Principal investigator 1 | PFIZER INC. | $37,458.55 | 12/31/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816234 |
| Principal investigator 1 | PFIZER INC. | $128,335.80 | 12/31/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228816333 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 12/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202531716 |
| Principal investigator 1 | PFIZER INC. | $21,325.50 | 12/23/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228815867 |
| Principal investigator 1 | Novo Nordisk AS | $2,540.00 | 12/22/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213720654 |
| Principal investigator 1 | Novo Nordisk AS | $6,702.80 | 12/22/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213809715 |
| Principal investigator 1 | ModernaTX, Inc. | $702.72 | 12/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978790 |
| Principal investigator 1 | ModernaTX, Inc. | $4,095.96 | 12/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978838 |
| Principal investigator 1 | ModernaTX, Inc. | $12,730.32 | 12/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978866 |
| Principal investigator 1 | ModernaTX, Inc. | $850.30 | 12/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978888 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 12/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 12/17/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $803.00 | 12/17/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $38.28 | 12/17/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771013 |
| Principal investigator 1 | PFIZER INC. | $25,879.75 | 12/17/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816663 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 12/16/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254171 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,176.50 | 12/16/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248254174 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,056.00 | 12/15/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812218 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $236.25 | 12/15/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812220 |
| Principal investigator 1 | ModernaTX, Inc. | $195.00 | 12/15/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978812 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 12/10/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253798 |
| Principal investigator 1 | ABBVIE INC. | $814.00 | 12/08/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202529616 |
| Principal investigator 1 | ABBVIE INC. | $9,166.12 | 12/04/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202526790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.39 | 12/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220771007 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253134 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253150 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253155 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $292.50 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253159 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $52.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253163 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253172 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $195.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253176 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253180 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253184 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 11/27/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253192 |
| Principal investigator 1 | ModernaTX, Inc. | $1,440.00 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978770 |
| Principal investigator 1 | ModernaTX, Inc. | $850.30 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978788 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978802 |
| Principal investigator 1 | ModernaTX, Inc. | $8,486.88 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978810 |
| Principal investigator 1 | ModernaTX, Inc. | $8,432.64 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978826 |
| Principal investigator 1 | ModernaTX, Inc. | $3,981.12 | 11/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978896 |
| Principal investigator 1 | PFIZER INC. | $5,923.75 | 11/27/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228812795 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 11/26/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228812749 |
| Principal investigator 1 | PFIZER INC. | $13,074.92 | 11/26/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228812760 |
| Principal investigator 1 | ModernaTX, Inc. | $2,785.90 | 11/21/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978910 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 11/20/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202524846 |
| Principal investigator 1 | Novo Nordisk AS | $1,800.00 | 11/20/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213815443 |
| Principal investigator 1 | PFIZER INC. | $44.00 | 11/19/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228812754 |
| Principal investigator 1 | PFIZER INC. | $10,662.75 | 11/15/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228813488 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,159.80 | 11/14/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC d/b/a Centricity Research | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211591305 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,289.00 | 11/14/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC d/b/a Centricity Research | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211591317 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $108.00 | 11/14/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC d/b/a Centricity Research | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211591322 |
| Principal investigator 1 | PFIZER INC. | $2,369.50 | 11/11/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228812807 |
| Principal investigator 1 | ABBVIE INC. | $1,100.00 | 11/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202523323 |
| Principal investigator 1 | ABBVIE INC. | $165.60 | 11/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202523345 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/06/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220815127 |
| Principal investigator 1 | ABBVIE INC. | $8,523.48 | 11/05/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522159 |
| Principal investigator 1 | ModernaTX, Inc. | $390.00 | 11/05/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978798 |
| Principal investigator 1 | Eli Lilly and Company | $3,528.07 | 11/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187879367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770993 |
| Principal investigator 1 | PFIZER INC. | $2,568.16 | 11/01/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228812801 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/30/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519765 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/30/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519807 |
| Principal investigator 1 | ABBVIE INC. | $165.60 | 10/30/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519845 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 10/30/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519877 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519547 |
| Principal investigator 1 | ABBVIE INC. | $1,100.00 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519549 |
| Principal investigator 1 | ABBVIE INC. | $281.52 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519589 |
| Principal investigator 1 | ABBVIE INC. | $255.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519591 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519593 |
| Principal investigator 1 | ABBVIE INC. | $800.00 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519595 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519607 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519625 |
| Principal investigator 1 | ABBVIE INC. | $165.60 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519627 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519629 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519631 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202519635 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978906 |
| Principal investigator 1 | ModernaTX, Inc. | $300.00 | 10/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978950 |
| Principal investigator 1 | Novo Nordisk AS | $700.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213731164 |
| Principal investigator 1 | Novo Nordisk AS | $1,500.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213733201 |
| Principal investigator 1 | Novo Nordisk AS | $375.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213736902 |
| Principal investigator 1 | Novo Nordisk AS | $465.62 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213738290 |
| Principal investigator 1 | Novo Nordisk AS | $800.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213754443 |
| Principal investigator 1 | Novo Nordisk AS | $1,500.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213763447 |
| Principal investigator 1 | Novo Nordisk AS | $825.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213764481 |
| Principal investigator 1 | Novo Nordisk AS | $700.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213777489 |
| Principal investigator 1 | Novo Nordisk AS | $5,080.40 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213806279 |
| Principal investigator 1 | Novo Nordisk AS | $2,900.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213816366 |
| Principal investigator 1 | Novo Nordisk AS | $582.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213822600 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213838594 |
| Principal investigator 1 | Novo Nordisk AS | $150.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213847851 |
| Principal investigator 1 | Novo Nordisk AS | $7,215.00 | 10/29/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213850389 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $195.67 | 10/28/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812216 |
| Principal investigator 1 | ModernaTX, Inc. | $6,324.48 | 10/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978854 |
| Principal investigator 1 | ModernaTX, Inc. | $4,344.78 | 10/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978856 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 10/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978964 |
| Principal investigator 1 | ABBVIE INC. | $108.00 | 10/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202518423 |
| Principal investigator 1 | ABBVIE INC. | $56.00 | 10/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202518425 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $844.80 | 10/23/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226088325 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,400.00 | 10/23/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226088331 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,175.00 | 10/23/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226088336 |
| Principal investigator 1 | ModernaTX, Inc. | $9,994.40 | 10/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978954 |
| Principal investigator 1 | ModernaTX, Inc. | $130.00 | 10/17/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978912 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $108.00 | 10/16/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC d/b/a Centricity Research | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211591309 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $800.00 | 10/16/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC d/b/a Centricity Research | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211591312 |
| Principal investigator 1 | ModernaTX, Inc. | $487.50 | 10/16/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978780 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,320.00 | 10/15/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812214 |
| Principal investigator 1 | PFIZER INC. | $47,390.00 | 10/11/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228817994 |
| Principal investigator 1 | ModernaTX, Inc. | $756.00 | 10/10/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978786 |
| Principal investigator 1 | ABBVIE INC. | $4,782.99 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202513851 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202515291 |
| Principal investigator 1 | ABBVIE INC. | $1,214.50 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202515761 |
| Principal investigator 1 | ABBVIE INC. | $56.00 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516155 |
| Principal investigator 1 | ABBVIE INC. | $147.18 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516283 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516293 |
| Principal investigator 1 | ABBVIE INC. | $2,939.10 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516319 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516425 |
| Principal investigator 1 | ABBVIE INC. | $54.00 | 10/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202516427 |
| Principal investigator 1 | Eli Lilly and Company | $244.68 | 10/08/2025 | Non-covered Recipient Entity COLUMBUS CLINICAL RESEARCH INC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187880343 |
| Principal investigator 1 | PFIZER INC. | $1,143.80 | 10/08/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228716353 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 10/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202513477 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 10/07/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248251364 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $147,192.32 | 10/02/2025 | Non-covered Recipient Entity CR SERVICES ACQUSITION US, LLC | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185547259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770981 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 10/01/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978958 |
| Principal investigator 1 | ModernaTX, Inc. | $4,038.54 | 09/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978808 |
| Principal investigator 1 | ModernaTX, Inc. | $4,919.04 | 09/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978816 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 09/27/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228836007 |
| Principal investigator 1 | PFIZER INC. | $28,270.55 | 09/24/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228836147 |
| Principal investigator 1 | Novo Nordisk AS | $72.10 | 09/19/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213770407 |
| Principal investigator 1 | Novo Nordisk AS | $3,257.80 | 09/19/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213775069 |
| Principal investigator 1 | Novo Nordisk AS | $3,705.00 | 09/19/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213780182 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 09/19/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213803242 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42,645.00 | 09/18/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812212 |
| Principal investigator 1 | ModernaTX, Inc. | $3,511.30 | 09/17/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978960 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 09/11/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202510758 |
| Principal investigator 1 | ABBVIE INC. | $165.60 | 09/11/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202510760 |
| Principal investigator 1 | PFIZER INC. | $8,293.25 | 09/09/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228836081 |
| Principal investigator 1 | PFIZER INC. | $79,220.00 | 09/09/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228836086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 09/08/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726055 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,065.05 | 09/05/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248249815 |
| Principal investigator 1 | ABBVIE INC. | $25,023.96 | 09/04/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202508582 |
| Principal investigator 1 | ABBVIE INC. | $1,134.00 | 09/04/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202509762 |
| Principal investigator 1 | ABBVIE INC. | $3,879.40 | 09/04/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202509764 |
| Principal investigator 1 | ModernaTX, Inc. | $65.00 | 09/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978800 |
| Principal investigator 1 | ModernaTX, Inc. | $78.00 | 09/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978832 |
| Principal investigator 1 | PFIZER INC. | $7,750.93 | 09/03/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228836001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770967 |
| Principal investigator 1 | ModernaTX, Inc. | $1,700.60 | 08/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978768 |
| Principal investigator 1 | ModernaTX, Inc. | $1,405.44 | 08/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978772 |
| Principal investigator 1 | ModernaTX, Inc. | $4,651.02 | 08/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978824 |
| Principal investigator 1 | ModernaTX, Inc. | $28,963.22 | 08/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978874 |
| Principal investigator 1 | ModernaTX, Inc. | $83.20 | 08/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 08/26/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770891 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 08/25/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202505689 |
| Principal investigator 1 | ABBVIE INC. | $350.52 | 08/25/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202505691 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 08/25/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202505697 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,832.43 | 08/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUSITION US, LLC | a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure | No dispute reported | 06/30/2026 | 1185547257 |
| Principal investigator 1 | Novo Nordisk AS | $21,258.90 | 08/22/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213777406 |
| Principal investigator 1 | PFIZER INC. | $2,369.50 | 08/21/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228843447 |
| Principal investigator 1 | ModernaTX, Inc. | $4,512.30 | 08/20/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978920 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 08/11/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726049 |
| Principal investigator 1 | ABBVIE INC. | $17,844.60 | 08/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202503031 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,336.00 | 08/06/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812210 |
| Principal investigator 1 | PFIZER INC. | $44,481.89 | 08/05/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228843683 |
| Principal investigator 1 | PFIZER INC. | $2,429.50 | 08/05/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228843758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770965 |
| Principal investigator 1 | PFIZER INC. | $47,930.00 | 08/01/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228843423 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $190,279.80 | 07/31/2025 | Non-covered Recipient Entity CR SERVICES ACQUSITION US, LLC | A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) | No dispute reported | 06/30/2026 | 1185547261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 07/28/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 07/28/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770887 |
| Principal investigator 1 | Eli Lilly and Company | $131.00 | 07/28/2025 | Non-covered Recipient Entity COLUMBUS CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187878801 |
| Principal investigator 1 | ModernaTX, Inc. | $2,108.16 | 07/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978836 |
| Principal investigator 1 | ModernaTX, Inc. | $1,148.40 | 07/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978848 |
| Principal investigator 1 | PFIZER INC. | $4,370.00 | 07/26/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228846858 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $11,819.50 | 07/18/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576480 |
| Principal investigator 1 | ModernaTX, Inc. | $3,363.10 | 07/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978940 |
| Principal investigator 1 | PFIZER INC. | $47,422.55 | 07/17/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228846850 |
| Principal investigator 1 | Novo Nordisk AS | $700.00 | 07/16/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213722267 |
| Principal investigator 1 | Novo Nordisk AS | $4,400.00 | 07/16/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213799364 |
| Principal investigator 1 | Novo Nordisk AS | $57.72 | 07/16/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213805843 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $14,700.78 | 07/15/2025 | Non-covered Recipient Entity CARE SERVICES ACQUISITION US | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190309848 |
| Principal investigator 1 | ModernaTX, Inc. | $951.60 | 07/14/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978834 |
| Principal investigator 1 | PFIZER INC. | $18,956.00 | 07/11/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228846843 |
| Principal investigator 1 | PFIZER INC. | $91,274.90 | 07/08/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228846895 |
| Principal investigator 1 | ABBVIE INC. | $6,131.68 | 07/02/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202495597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770963 |
| Principal investigator 1 | PFIZER INC. | $2,188.00 | 07/01/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228846803 |
| Principal investigator 1 | ModernaTX, Inc. | $40.30 | 06/30/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007483 |
| Principal investigator 1 | ModernaTX, Inc. | $3,674.88 | 06/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978764 |
| Principal investigator 1 | ModernaTX, Inc. | $20,051.46 | 06/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978796 |
| Principal investigator 1 | ModernaTX, Inc. | $7,729.92 | 06/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978804 |
| Principal investigator 1 | PFIZER INC. | $5,503.96 | 06/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228852090 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,778.00 | 06/26/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812208 |
| Principal investigator 1 | PFIZER INC. | $154,723.10 | 06/26/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228851115 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.00 | 06/24/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812206 |
| Principal investigator 1 | Eli Lilly and Company | $6,435.00 | 06/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] | No dispute reported | 06/30/2026 | 1187880976 |
| Principal investigator 1 | ModernaTX, Inc. | $14,405.76 | 06/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978776 |
| Principal investigator 1 | ModernaTX, Inc. | $3,847.14 | 06/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978814 |
| Principal investigator 1 | ModernaTX, Inc. | $15,595.58 | 06/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978902 |
| Principal investigator 1 | ModernaTX, Inc. | $8,502.00 | 06/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978956 |
| Principal investigator 1 | ModernaTX, Inc. | $5,796.70 | 06/18/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007529 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 06/17/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202491773 |
| Principal investigator 1 | PFIZER INC. | $2,751.98 | 06/14/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228851109 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 06/13/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978936 |
| Principal investigator 1 | PFIZER INC. | $89,513.10 | 06/10/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228852083 |
| Principal investigator 1 | ABBVIE INC. | $179.00 | 06/05/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202490409 |
| Principal investigator 1 | ABBVIE INC. | $19,029.50 | 06/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202488331 |
| Principal investigator 1 | ABBVIE INC. | $413.00 | 06/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202488333 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 06/02/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770961 |
| Principal investigator 1 | PFIZER INC. | $18,500.00 | 05/30/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228855668 |
| Principal investigator 1 | PFIZER INC. | $7,882.14 | 05/30/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228858403 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486897 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486907 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486909 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486911 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486913 |
| Principal investigator 1 | ABBVIE INC. | $1,024.20 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486931 |
| Principal investigator 1 | ABBVIE INC. | $4,375.00 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486933 |
| Principal investigator 1 | ABBVIE INC. | $332.40 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202487053 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 05/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202487055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 05/29/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726043 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486441 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486459 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486461 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486463 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486465 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486467 |
| Principal investigator 1 | ABBVIE INC. | $165.60 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486475 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486477 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486485 |
| Principal investigator 1 | ABBVIE INC. | $110.40 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486487 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486515 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486517 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486519 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486521 |
| Principal investigator 1 | ABBVIE INC. | $55.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202486525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 05/28/2025 | Non-covered Recipient Entity Centricity Research | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220726019 |
| Principal investigator 1 | ModernaTX, Inc. | $1,700.60 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978766 |
| Principal investigator 1 | ModernaTX, Inc. | $11,292.60 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978784 |
| Principal investigator 1 | ModernaTX, Inc. | $3,341.91 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978872 |
| Principal investigator 1 | ModernaTX, Inc. | $46,730.88 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978876 |
| Principal investigator 1 | ModernaTX, Inc. | $28,577.90 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978894 |
| Principal investigator 1 | ModernaTX, Inc. | $12,854.40 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007491 |
| Principal investigator 1 | ModernaTX, Inc. | $55,291.60 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007493 |
| Principal investigator 1 | ModernaTX, Inc. | $9,079.20 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007523 |
| Principal investigator 1 | PFIZER INC. | $3,789.22 | 05/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228858362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 05/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770883 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.00 | 05/27/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812204 |
| Principal investigator 1 | PFIZER INC. | $1,089.15 | 05/27/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707281 |
| Principal investigator 1 | PFIZER INC. | $1,089.15 | 05/27/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840701 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $200.00 | 05/26/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726255 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 05/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978898 |
| Principal investigator 1 | Novo Nordisk AS | $44.88 | 05/23/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213829413 |
| Principal investigator 1 | Novo Nordisk AS | $616.00 | 05/23/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213847951 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 05/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213798483 |
| Principal investigator 1 | Novo Nordisk AS | $4,855.50 | 05/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213818083 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707279 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707455 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840680 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840693 |
| Principal investigator 1 | PFIZER INC. | $9,913.46 | 05/19/2025 | Non-covered Recipient Entity Centricity Research Columbus | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707101 |
| Principal investigator 1 | PFIZER INC. | $9,913.46 | 05/19/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228842725 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $400.00 | 05/19/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226088297 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $292.50 | 05/16/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244003 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,300.00 | 05/16/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244006 |
| Principal investigator 1 | ModernaTX, Inc. | $6,576.70 | 05/16/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978922 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $52.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243513 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $292.50 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243525 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243538 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243550 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243554 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $195.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243558 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $65.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243561 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243565 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243569 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243574 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $65.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243580 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243587 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243591 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $65.00 | 05/15/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243600 |
| Principal investigator 1 | ModernaTX, Inc. | $715.00 | 05/15/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007505 |
| Principal investigator 1 | PFIZER INC. | $41,627.85 | 05/15/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228858355 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $338.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243354 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243357 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,248.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243361 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,460.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243366 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243369 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243373 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $487.50 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243435 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $17,836.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243439 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,376.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243444 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $17,836.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243448 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $52.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243452 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,222.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243456 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $26.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243460 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243465 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,248.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243469 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $97.50 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243473 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $975.00 | 05/14/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243477 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,012.00 | 05/09/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812202 |
| Principal investigator 1 | PFIZER INC. | $21,336.15 | 05/08/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228858399 |
| Principal investigator 1 | ABBVIE INC. | $1,192.20 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202483079 |
| Principal investigator 1 | ABBVIE INC. | $17,498.65 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202483157 |
| Principal investigator 1 | ABBVIE INC. | $567.00 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202483923 |
| Principal investigator 1 | ModernaTX, Inc. | $45.50 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978818 |
| Principal investigator 1 | ModernaTX, Inc. | $71.50 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978858 |
| Principal investigator 1 | ModernaTX, Inc. | $312.00 | 05/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978890 |
| Principal investigator 1 | ModernaTX, Inc. | $1,658.80 | 05/02/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978944 |
| Principal investigator 1 | ABBVIE INC. | $200.00 | 05/01/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202480849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770959 |
| Principal investigator 1 | PFIZER INC. | $8,478.39 | 05/01/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228858410 |
| Principal investigator 1 | ModernaTX, Inc. | $4,118.40 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007489 |
| Principal investigator 1 | ModernaTX, Inc. | $10,255.70 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007495 |
| Principal investigator 1 | ModernaTX, Inc. | $7,566.00 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007497 |
| Principal investigator 1 | ModernaTX, Inc. | $2,675.40 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007501 |
| Principal investigator 1 | ModernaTX, Inc. | $3,026.40 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007507 |
| Principal investigator 1 | ModernaTX, Inc. | $13,020.80 | 04/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007537 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,569.20 | 04/23/2025 | Non-covered Recipient Entity AVENTIV RESEARCH INC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242535 |
| Principal investigator 1 | ModernaTX, Inc. | $5,864.30 | 04/23/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978908 |
| Principal investigator 1 | Novo Nordisk AS | $1,197.00 | 04/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213737590 |
| Principal investigator 1 | Novo Nordisk AS | $383.00 | 04/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213740153 |
| Principal investigator 1 | Novo Nordisk AS | $4,898.40 | 04/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213741304 |
| Principal investigator 1 | Novo Nordisk AS | $205.94 | 04/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213794149 |
| Principal investigator 1 | ModernaTX, Inc. | $827.84 | 04/16/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007519 |
| Principal investigator 1 | PFIZER INC. | $7,576.01 | 04/16/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228858321 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,637.00 | 04/11/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812200 |
| Principal investigator 1 | PFIZER INC. | $3,448.16 | 04/09/2025 | Non-covered Recipient Entity Centricity Research Columbus | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707277 |
| Principal investigator 1 | PFIZER INC. | $3,448.16 | 04/09/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228842698 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $400.00 | 04/08/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576477 |
| Principal investigator 1 | ABBVIE INC. | $6,122.28 | 04/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202470996 |
| Principal investigator 1 | ModernaTX, Inc. | $130.00 | 04/02/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978930 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770957 |
| Principal investigator 1 | PFIZER INC. | $12,930.60 | 03/31/2025 | Non-covered Recipient Entity Centricity Research Columbus | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707379 |
| Principal investigator 1 | PFIZER INC. | $12,930.60 | 03/31/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228842705 |
| Principal investigator 1 | Novo Nordisk AS | $681.00 | 03/28/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213731443 |
| Principal investigator 1 | Novo Nordisk AS | $33,653.75 | 03/28/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213741033 |
| Principal investigator 1 | Novo Nordisk AS | $836.88 | 03/28/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213802857 |
| Principal investigator 1 | PFIZER INC. | $55,097.40 | 03/28/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228861212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,980.00 | 03/24/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $288.00 | 03/24/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 03/24/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,200.00 | 03/24/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726219 |
| Principal investigator 1 | ModernaTX, Inc. | $1,054.08 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978762 |
| Principal investigator 1 | ModernaTX, Inc. | $161.19 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978880 |
| Principal investigator 1 | ModernaTX, Inc. | $121.53 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978882 |
| Principal investigator 1 | ModernaTX, Inc. | $15,132.00 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007503 |
| Principal investigator 1 | ModernaTX, Inc. | $1,337.70 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007515 |
| Principal investigator 1 | ModernaTX, Inc. | $15,579.20 | 03/24/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007533 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/24/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707459 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/24/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840734 |
| Principal investigator 1 | PFIZER INC. | $18,500.00 | 03/22/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228861220 |
| Principal investigator 1 | ModernaTX, Inc. | $546.00 | 03/21/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978916 |
| Principal investigator 1 | ModernaTX, Inc. | $273.00 | 03/21/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.43 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726179 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.86 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.25 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.76 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.29 | 03/19/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726253 |
| Principal investigator 1 | ModernaTX, Inc. | $2,828.80 | 03/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978928 |
| Principal investigator 1 | ModernaTX, Inc. | $4,612.40 | 03/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978934 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,445.00 | 03/17/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812198 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 03/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228716319 |
| Principal investigator 1 | PFIZER INC. | $677.05 | 03/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228814736 |
| Principal investigator 1 | PFIZER INC. | $793.65 | 03/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228814800 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $400.00 | 03/14/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226088253 |
| Principal investigator 1 | ModernaTX, Inc. | $504.00 | 03/12/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978852 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 03/12/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978868 |
| Principal investigator 1 | ModernaTX, Inc. | $390.00 | 03/12/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978962 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707377 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840707 |
| Principal investigator 1 | PFIZER INC. | $3,437.00 | 03/08/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228861806 |
| Principal investigator 1 | ABBVIE INC. | $21,752.57 | 03/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202461752 |
| Principal investigator 1 | ModernaTX, Inc. | $3,311.36 | 03/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007487 |
| Principal investigator 1 | ModernaTX, Inc. | $624.00 | 03/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007527 |
| Principal investigator 1 | ModernaTX, Inc. | $91.00 | 03/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978794 |
| Principal investigator 1 | ModernaTX, Inc. | $71.50 | 03/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.65 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $519.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.43 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $168.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $519.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $60.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.50 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $519.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $286.86 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.39 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.02 | 03/05/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726251 |
| Principal investigator 1 | ModernaTX, Inc. | $943.80 | 03/05/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978952 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.89 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 02/28/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726037 |
| Principal investigator 1 | ModernaTX, Inc. | $208.00 | 02/28/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007509 |
| Principal investigator 1 | ModernaTX, Inc. | $6,802.40 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978806 |
| Principal investigator 1 | ModernaTX, Inc. | $3,521.76 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978828 |
| Principal investigator 1 | ModernaTX, Inc. | $6,392.76 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978842 |
| Principal investigator 1 | ModernaTX, Inc. | $31,047.84 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978860 |
| Principal investigator 1 | ModernaTX, Inc. | $46,933.74 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978862 |
| Principal investigator 1 | ModernaTX, Inc. | $15,108.48 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978864 |
| Principal investigator 1 | ModernaTX, Inc. | $19,784.70 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978878 |
| Principal investigator 1 | ModernaTX, Inc. | $19,162.32 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978900 |
| Principal investigator 1 | ModernaTX, Inc. | $17,804.80 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007499 |
| Principal investigator 1 | ModernaTX, Inc. | $31,658.90 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007513 |
| Principal investigator 1 | ModernaTX, Inc. | $16,645.20 | 02/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007521 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,854.80 | 02/26/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226087972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 02/25/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 02/25/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 02/25/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770879 |
| Principal investigator 1 | ModernaTX, Inc. | $13,486.20 | 02/21/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978914 |
| Principal investigator 1 | Novo Nordisk AS | $9,202.05 | 02/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213765559 |
| Principal investigator 1 | Novo Nordisk AS | $300.00 | 02/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213775228 |
| Principal investigator 1 | Novo Nordisk AS | $6,612.00 | 02/21/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213837648 |
| Principal investigator 1 | ModernaTX, Inc. | $40.30 | 02/19/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978942 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $790.76 | 02/17/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576455 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $682.76 | 02/17/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576458 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $2,633.04 | 02/17/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576464 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $1,779.98 | 02/17/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576468 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707103 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707381 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840721 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/17/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228840727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,150.00 | 02/14/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 02/14/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 02/14/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726159 |
| Principal investigator 1 | ModernaTX, Inc. | $403.20 | 02/14/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978756 |
| Principal investigator 1 | ModernaTX, Inc. | $1,040.00 | 02/14/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978822 |
| Principal investigator 1 | ModernaTX, Inc. | $70.81 | 02/14/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978886 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,500.00 | 02/12/2025 | Non-covered Recipient Entity AVENTIV RESEARCH | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185547255 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 02/12/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978932 |
| Principal investigator 1 | PFIZER INC. | $2,350.00 | 02/12/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707457 |
| Principal investigator 1 | ModernaTX, Inc. | $88.79 | 02/10/2025 | Non-covered Recipient Entity AVENTIV RESEARCH, INC. COLUMBUS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978760 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 02/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978782 |
| Principal investigator 1 | ModernaTX, Inc. | $856.80 | 02/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978844 |
| Principal investigator 1 | ModernaTX, Inc. | $97.50 | 02/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978892 |
| Principal investigator 1 | ABBVIE INC. | $16,332.30 | 02/06/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202449825 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $200.00 | 02/05/2025 | Non-covered Recipient Entity Aventiv Research, Inc. | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211576472 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 02/05/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978948 |
| Principal investigator 1 | Novo Nordisk AS | $4,698.00 | 02/05/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213749031 |
| Principal investigator 1 | Novo Nordisk AS | $3,150.00 | 02/05/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH COLUMBUS | NN9536-4512 | No dispute reported | 06/30/2026 | 1213751545 |
| Principal investigator 1 | Eli Lilly and Company | $84,702.00 | 02/04/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187880291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 02/03/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726161 |
| Principal investigator 1 | PFIZER INC. | $981.24 | 02/03/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814741 |
| Principal investigator 1 | PFIZER INC. | $837.08 | 02/03/2025 | Non-covered Recipient Entity Centricity Research Columbus Ohio Multispecialty | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770953 |
| Principal investigator 1 | Eli Lilly and Company | $669.09 | 01/31/2025 | Non-covered Recipient Entity COLUMBUS CLINICAL RESEARCH INC | A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187876613 |
| Principal investigator 1 | Eli Lilly and Company | $1,371.61 | 01/31/2025 | Non-covered Recipient Entity COLUMBUS CLINICAL RESEARCH INC | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187878797 |
| Principal investigator 1 | Novo Nordisk AS | $290.00 | 01/30/2025 | Non-covered Recipient Entity CENTRICITY RESEARCH | NN9536-7752 | No dispute reported | 06/30/2026 | 1213752175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,137.44 | 01/29/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726095 |
| Principal investigator 1 | ModernaTX, Inc. | $252.00 | 01/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978846 |
| Principal investigator 1 | ModernaTX, Inc. | $273.00 | 01/29/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978924 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 01/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.62 | 01/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.58 | 01/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 01/27/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770873 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,436.00 | 01/27/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812196 |
| Principal investigator 1 | Eli Lilly and Company | $6,156.64 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187878013 |
| Principal investigator 1 | ModernaTX, Inc. | $5,174.64 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978758 |
| Principal investigator 1 | ModernaTX, Inc. | $1,512.06 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978774 |
| Principal investigator 1 | ModernaTX, Inc. | $850.30 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978778 |
| Principal investigator 1 | ModernaTX, Inc. | $6,704.82 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978830 |
| Principal investigator 1 | ModernaTX, Inc. | $5,621.76 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978850 |
| Principal investigator 1 | ModernaTX, Inc. | $765.60 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978870 |
| Principal investigator 1 | ModernaTX, Inc. | $3,193.72 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252978884 |
| Principal investigator 1 | ModernaTX, Inc. | $19,671.60 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007511 |
| Principal investigator 1 | ModernaTX, Inc. | $4,347.20 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007517 |
| Principal investigator 1 | ModernaTX, Inc. | $12,485.20 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007531 |
| Principal investigator 1 | ModernaTX, Inc. | $17,659.20 | 01/27/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.43 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.00 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.23 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.48 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.92 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/22/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726153 |
| Principal investigator 1 | ModernaTX, Inc. | $168.75 | 01/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252978792 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 01/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252978820 |
| Principal investigator 1 | ModernaTX, Inc. | $6,559.80 | 01/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978938 |
| Principal investigator 1 | ModernaTX, Inc. | $1,091.12 | 01/22/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007485 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $116,055.40 | 01/22/2025 | Non-covered Recipient Entity Cr Services Acquisition Us Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1226087966 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.04 | 01/16/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726057 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $46,410.00 | 01/16/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812194 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,801.00 | 01/15/2025 | Non-covered Recipient Entity CR SERVICES ACQUSITION US, LLC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185547253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $250.00 | 01/15/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $480.00 | 01/15/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726151 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 01/15/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252978946 |
| Principal investigator 1 | Eli Lilly and Company | $222,598.90 | 01/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A STUDY OF TIRZEPATIDE (LY3298176) ONCE WEEKLY IN ADOLESCENT PARTICIPANTS WHO HAVE OBESITY, OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | No dispute reported | 06/30/2026 | 1187878623 |
| Principal investigator 1 | Eli Lilly and Company | $41,585.38 | 01/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187878625 |
| Principal investigator 1 | Eli Lilly and Company | $340,896.55 | 01/07/2025 | Non-covered Recipient Entity CR SERVICES ACQUISITION US LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187883796 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.00 | 01/06/2025 | Non-covered Recipient Entity Centricity Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812192 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $79,946.37 | 01/03/2025 | Non-covered Recipient Entity CR SERVICES ACQUSITION US, LLC | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185547251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 01/02/2025 | Non-covered Recipient Entity Centricity Research | Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis | No dispute reported | 06/30/2026 | 1220726149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity Centricity Research | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220726021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Aventiv Research Dublin | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220770951 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $20,790.19 | 01/01/2025 | Non-covered Recipient Entity AVENTIV RESEARCH GROVE CITY | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190309778 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $815.52 | 01/01/2025 | Non-covered Recipient Entity CARE SERVICES ACQUISITION US | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190309850 |
| Principal investigator 1 | PFIZER INC. | $6,650.00 | 01/01/2025 | Non-covered Recipient Entity CR Services Acquisition US LLC dba Centricity Research | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228863500 |